November 8, 2021 09:22 AM EST
Pharma
Marketing

Ab­bott plots new paths to clin­i­cal tri­al di­ver­si­ty, join­ing bio­phar­ma push for broad­er in­clu­sion

Beth Snyder Bulik

Senior Editor

Clin­i­cal tri­als have a di­ver­si­ty prob­lem. That’s the open­ing state­ment on Ab­bott’s new web­site to pro­mote its lat­est di­ver­si­ty ef­forts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times